Jennie Ekbeck, CEO Umeå Biotech Incubator.

Pressmeddelande - 22 April 2020 11:56

New vaccine facility in Umeå creates more jobs for city’s thriving life science industry

Publicly listed Diamyd Medical is to open a new vaccine manufacturing facility in Umeå.

“This is fantastic news and demonstrates that Umeå is a growing life science hub,” says Jennie Ekbeck, CEO of Umeå Biotech Incubator.

Diamyd Medical is developing a vaccine for diabetes type 1. A manufacturing plant is now being opened in premises previously operated by Sobi (Swedish Orphan Biovitrum) at Ersboda in Umeå. The 1,000 square-meter building contains clean rooms, laboratories and offices.

“The investment being made by Diamyd Medical into systems, instruments and personnel amounts to approximately SEK 20 million. This is a huge investment in Umeå and we are delighted they have chosen to base the facility here,” says Jennie Ekbeck.

The move will create a number of new jobs in Umeå, which Jennie Ekbeck believes is important for the region’s life science industry as a whole. Today there are several companies with production sites in Umeå: APL produces sterile medicines, Nordic Biomarker manufactures reagents for blood clot diagnostics and Cytiva (formerly GE Healthcare) manufactures laboratory equipment.

“Umeå Biotech Incubator's goal is to create the ideal conditions for industry growth in Västerbotten and Sweden. It is important for our region that there are several employers for people to choose from, as it increases the attraction of wanting to stay or move here,” says Jennie Ekbeck.

For companies to grow more expertise in industrial life science is needed. Jennie Ekbeck hopes that Diamyd Medical's establishment in Umeå will help increase interest in life science education at universities.

“At Umeå Biotech Incubator we want to contribute to an increase in the number of life science companies with more than 20 employees in the region, because then conditions for industrial specialisation are created. That’s why we are particularly excited about Diamyd Medical's decision to open up here.”

Diamyd Medical's Class B shares are traded on the Nasdaq First North Growth Market.

For further information please contact:

Jennie Ekbeck
CEO, Umeå Biotech Incubator
+46 90-15 49 77
jennie.ekbeck@ubi.se

Umeå Biotech Incubator (UBI) is one of Sweden’s state-of-the-art business incubators within the life sciences. We help researchers to use their data to the benefit of patients and citizens, improving their health. We support and train entrepreneurs in the fields of pharmaceuticals, diagnostics and medical engineering, and act as a bridge between academia, medicine and the business community.

Kontakter

Tomas Ruuth

Presskontakt Kommunikationsansvarig PR & Communications tomas.ruuth@ubi.se 072-4024697 www.ubi.se

Relaterad media Ladda ner bilder för medieanvändning

Jennie Ekbeck, CEO Umeå Biotech Incubator.
Licens: Medieanvändning
Innehållet får laddas ner, användas och delas i olika mediekanaler av t.ex. journalister, bloggare, krönikörer, opinionsbildare etc., i syftet att förmedla, redogöra för och kommentera ert pressmeddelande, inlägg eller information, så länge innehållet används oförändrat och i dess helhet. Upphovsmannen ska anges i den omfattning och på det sätt god sed kräver (vilket bl.a. innebär att fotografer till bilder nästan alltid måste anges).
Av: Patrick Trädgårdh
Filformat: .jpg
Storlek: 5568 x 3712, 5,84 MB

Relaterat innehåll

21 April 2020 12:16

QureTech Bio granted millions to fight antibiotic resistance

Umeå life science company QureTech Bio has received a SEK 3 million grant from the Swelife innovation programme (funded by the Swedish Government via Vinnova) to make antibiotic-resistant bacteria sensitive to different antibiotics again. “We are delighted to receive this grant, as it will enable us to create a product that can help patients and save lives,” says Fredrik Almqvist, CEO.

Simon Dahl and Mikael Östberg, founders Memotus.

2 April 2020 13:13

Memotus App at forefront of digital healthcare

Umea-based health technology company Instrube Health AB has developed a new communication app for the healthcare industry. Called Memotus, the new messaging app and platform is designed for both healthcare providers and patients, allowing them to manage consultations and follow-up visits digitally.

24 Mars 2020 08:50

Lipigon signs new deal in billion dollar market

Umeå-based Lipigon Pharmaceuticals has signed a new deal and taken over the patent portfolio for a number of drug candidates that could help treat cardiovascular diseases. “The market in treatments for various blood fat disorders amounts to several billion dollars. This is a very important opportunity for us,” says Stefan K Nilsson, CEO of Lipigon.

Marie-Louise Hammarström, Sten Hammarström, Anne Israelsson, Gudrun Lindmark, Harald Hedman, Lina Olsson, Linn Heikkilä at HiloProbe.

10 Juni 2020 08:31

HiloProbe attracts millions in new investment round

Umeå biotech company HiloProbe has attracted millions in new investment capital after successfully developing a diagnostic and prognostic product for colon and rectal cancer. “Capital is crucial for getting our product to patients and helping them,” says Lina Olsson, HiloProbe’s CEO.

20 Maj 2020 08:00

Agrisera acquired by Uppsala life science company Olink

After many years of private ownership, Vännäs-based Agrisera has been acquired by Swedish biotech company Olink Proteomics AB. “The Agrisera brand was very strong in itself, but this step offers us great opportunities that can benefit both our customers and partners,” says Erika Gelfgren, CEO of Agrisera.

12 Oktober 2020 08:30

Diamyd Medical moves pharmaceutical production from USA to Umeå – hires

A recruitment drive is underway at Diamyd Medical's new vaccine facility in Umeå after the company announced it is moving production of the GAD65 protein, the active substance in the diabetes vaccine Diamyd, from abroad to Sweden. “This move gives us greater control and more knowledge about our study drug”, says Maja Johansson, Site Manager in Umeå.

17 Augusti 2020 08:09

New and Different Facebook Group Helping Life Science Companies

A new Facebook group is enabling companies in Umeå to buy and sell second-hand laboratory equipment, as well as gain access to cheaper lab services. “Many life science companies are often in need of a laboratory, but new equipment is expensive and requires a great deal of knowledge to operate. This new group allows companies to sustainably support each other,” says Jennie Ekbeck, CEO of UBI.

16 December 2020 08:00

New AI solution being tested at Umeå vaccine facility

A new AI solution for sustainable production is to be tested at Diamyd Medical's vaccine manufacturing facility in Umeå. It is hoped, once the solution has been refined, that it can be introduced in companies throughout Sweden. “This represents a unique opportunity that we do not see that often in Sweden”, says Ulf Hannelius, CEO of Diamyd Medical.